We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Navidea Biopharmaceuticals Inc | AMEX:NAVB | AMEX | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.0779 | 0 | 01:00:00 |
|
(Exact name of registrant as specified in its charter)
|
|
|
|
(State or other jurisdiction
|
(Commission
|
(IRS Employer
|
of incorporation)
|
File Number)
|
Identification No.)
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant's telephone number, including area code
|
(
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol(s)
|
Name of exchange on which registered
|
|
|
|
|
|
|
Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
Item 5.07 | Submission of Matters to a Vote of Security Holders. |
For | Against | Abstain |
47,907,056,197 | 16,512,206,711 | 349,038,690 |
For | Against | Abstain |
39,987,334 | 15,937,845 | 337,284 |
Item 8.01 | Other Events |
Item 9.01 | Financial Statements and Exhibits. |
Exhibit
|
|
Number
|
Exhibit Description
|
10.1
|
|
99.1
|
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
Navidea Biopharmaceuticals, Inc.
|
||
Date: July 28, 2023
|
By:
|
/s/ Joseph W. Meyer
|
Joseph W. Meyer
Director, Finance and Accounting
(Principal Financial Officer)
|
Exhibit 10.1
July 26, 2023
Mr. Craig Dais
Dear Craig,
I am pleased to offer you the position of Chief Financial Officer for Navidea Biopharmaceuticals, Inc. (the "Company"). As the Chief Financial Officer, you will be responsible for tracking cash flow, analyzing strengths/weaknesses in the Company's finances and overseeing all aspects of its financial success. You will report directly to the Chief Medical Officer.
Duties and Responsibilities
● |
Recruit Hire and Retain Industry Leading Talent for the Company |
● |
Directs the preparation of all financial statements, including income statements, balance sheets, shareholder reports, tax returns, and governmental agency reports. |
● |
Company sales and profit projections to actual figures and budgeted expenses to actual expenses; makes or oversees any necessary adjustments to future projections and budgets. |
● |
Reviews planning process and suggests improvements to current methods. |
● |
Analyzes operations to identify areas in need of reorganization, downsizing, or elimination. |
● |
Works with the CMO and other executives to coordinate planning and establish priorities for the planning process. |
● |
Studies long-range economic trends and projects their impact on future growth in sales and market share. |
● |
Identifies opportunities for expansion into new product areas. |
● |
Oversees investment of funds and works with investment bankers to raise additional capital required for expansion. |
● |
Provide Key Vendor Relationship Support |
● |
Manage and Support designated NAVB associates |
● |
Attend/Support NAVB Weekly Team Meetings facilitated by G2G Ventures |
● |
Support Investor discussions |
● |
Other duties as assigned |
Annual Compensation Details
Annual Salary: $200,000
Annual Cash Bonus Target: 20% of Annual Salary - Based upon achieving Company Plan
Annual Stock Option Target: 150,000 Company Stock Options to be awarded annually - Based upon achieving Company Plan (2023 stock option award (if achieved) will not be pro-rate for start date)
Access to Company Medical, Dental and Vision benefits within 30 days of start date
Paid Vacation: 4 weeks per year
CPA/CPE: License and renewal reimbursement up to $1,000 per year
Start Date: July 28, 2023
Your employment, like that of all other employees of the Company, will be "at will." This means that either you or the Company may terminate the employment relationship, at any time, with or without cause.
Should these terms be acceptable to you, please sign and return this agreement within 3 business days of receipt. We appreciate your contributions to the Company and look forward to continuing to work with you.
Sincerely,
Signed and accepted by:
/s/Craig A. Dais | Craig A. Dais | |
July 26,2023 | ||
Date |
Exhibit 99.1
Press Release
Navidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial Officer
Following the Company’s Fix, Fund, Propel approach, Mr. Dais’s hire strengthens financial expertise, leadership, and oversight, along with continuing Navidea’s focus on advancing innovative technology to market.
DUBLIN, Ohio, July 27, 2023 (BUSINESS WIRE) -- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the hiring of Craig A. Dais, CPA in the position of Chief Financial Officer (CFO), reporting directly to the Company’s Chief Medical Officer. Mr. Dais’s hiring aligns with the Company’s stated objectives and its Fix, Fund, Propel approach to advancing innovative technology to market.
Financial Expertise, Leadership, and Oversight
Craig A. Dais’s hiring in the role of CFO, strengthens the Company’s financial expertise and oversight, supported by G2G Ventures as Executive Consultants, with demonstrated expertise in accounting, financial modeling, capital development, and strong growth-oriented leadership within private and publicly-held organizations. In his role, he is responsible for overseeing all aspects of Navidea’s financial success, including the preparation of all financial statements, reporting and analysis, the active management of the Company’s cash flows, and the development of expert teams responsible for managing and tracking financial activities.
“Craig is an active and experienced accounting and finance leader with the ability to see both the details and the big picture,” said Michael Blue, M.D., FACEP, Navidea’s Chief Medical Officer. “He is a self-motivated leader with expertise in developing strong teams that can help the Company grow by providing insights, reporting, and financial acumen. His financial leadership will help bring Navidea's technology and assets to the forefront.”
Mr. Dais continues an impactful career as financial executive, leader, and Certified Public Accountant, having served in various roles of increasing responsibility over 30 years. His recent experience includes serving as Chief Financial Officer at Colorado Pain Care, LLC, (Fractional) Chief Financial Officer at Ascent CFO Solutions, Chief Financial Officer at Duffy Crane & Hauling, Vice President of Finance at Pendum LLC and other leadership positions with public and private organizations. Craig began his career in finance with KPMG Peat Marwick. Mr. Dais earned a Bachelor of Science in Accounting, along with a Minor in Business, from Metropolitan State University of Denver, and is (inactive status) a Certified Public Accountant.
“I am thrilled to have the opportunity to join Navidea’s team as Chief Financial Officer, and eager to get started,” said Mr. Dais. “I believe my experience and career has led me to this role, and I believe Navidea’s transformative technology can improve lives around the world. My goal is to get to work using my experience to make that happen.”
About Navidea
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products based on its Manocept platform to enhance patient care by identifying the sites and pathways of disease and enable better diagnostic accuracy, clinical decision-making, and targeted treatment. Navidea’s Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Manocept platform serves as the molecular backbone of Tc99m tilmanocept, the first product developed and commercialized by Navidea based on the platform. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the Company’s pipeline through global partnering and commercialization efforts. For more information, visit www.navidea.com.
About G2G Ventures
G2G Ventures is a Colorado-based private equity firm focused on empowering organizations to reach their full potential through investment and consulting services. Specializing in creating long-term partnerships with trusted investors and established businesses, G2G Ventures draws on strong internal balance sheet liquidity, augmented by trusted investor capital, to craft bespoke capital solutions which include private equity investment, venture capital participation, and mezzanine debt options. Beyond financial investment, G2G Ventures provides accretive consulting services to help clarify strategic goals and key performance indicators (KPIs), evolve financial processes, and enhance operational effectiveness. To learn more about how G2G Ventures is a growth partner for enduring business, connect with our team.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends affecting the financial condition of our business. Forward-looking statements include our expectations regarding pending litigation and other matters. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, among other things: our history of operating losses and uncertainty of future profitability; the final outcome of any pending litigation; our ability to successfully complete research and further development of our drug candidates; the timing, cost and uncertainty of obtaining regulatory approvals of our drug candidates; our ability to successfully commercialize our drug candidates; dependence on royalties and grant revenue; our ability to implement our growth strategy; anticipated trends in our business; our limited product line and distribution channels; advances in technologies and development of new competitive products; our ability to comply with the NYSE American continued listing standards; our ability to maintain effective internal control over financial reporting; the impact of the current coronavirus pandemic; and other risk factors detailed in our most recent Annual Report on Form 10-K and other SEC filings. You are urged to carefully review and consider the disclosures found in our SEC filings, which are available at http://www.sec.gov or at http://ir.navidea.com.
Investors are urged to consider statements that include the words “will,” “may,” “could,” “should,” “plan,” “continue,” “designed,” “goal,” “forecast,” “future,” “believe,” “intend,” “expect,” “anticipate,” “estimate,” “project,” and similar expressions, as well as the negatives of those words or other comparable words, to be uncertain forward-looking statements.
You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be incorrect. We undertake no obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this report. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this report may not occur and actual results could differ materially from those anticipated or implied in the forward-looking statements.
Investor Relations Contact
Navidea Biopharmaceuticals, Inc.
G2G Ventures - Executive Consultant
Theodore Gerbick
Chief Marketing Officer
tgerbick@g2g.ventures
1 Year Navidea Biopharmaceuticals Chart |
1 Month Navidea Biopharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions